German biotech firm BioNTech (22UAy.DE), has agreed to acquire domestic peer CureVac, for about $1.25 billion worth of BioNTech shares, it said on Thursday, to boost its work on new mRNA-based cancer treatments.
Under the deal, which pairs two former rivals in the race to develop COVID-19 vaccines, CureVac shareholders stand to receive a premium of 55% over the three-month average share price, and leave them with a stake of about 4%-6% in BioNTech, the suitor said.
CureVac's Frankfurt-listed shares surged 27% to a five-month high, valuing the company at €1.04 billion ($1.2 billion), while BioNTech shares were down 2%.
The deal further underscores BioNTech's long-term pursuit of new cancer treatments as it aims to show that its success as Pfizer's COVID-19 vaccine partner, which left its balance sheet flush with billions of euros in cash, was not a fluke.
"With the acquisition, BioNTech aims to strengthen the research, development, manufacturing, and commercialization of investigational mRNA-based cancer immunotherapy," the company said.
CureVac opted to focus on oncology about a year ago when it agreed to sell its remaining influenza and COVID-19 vaccine development to alliance partner GSK.
It had previously cut jobs as it sought to move beyond its failure to develop an mRNA-based COVID vaccine during the pandemic.
GERMAN BIOTECH CHAMPION
The agreement is also set to end CureVac's years-long legal fight over alleged mRNA patent infringement by BioNTech and for a share of vaccine revenues, where CureVac has made little progress.
CureVac shares were worth as much as €120 in December 2020 on hopes it would develop a COVID vaccine, more than double their initial public offer value in August of that year. They are now trading at €4.65.
BioNTech won a major shot in the arm for its cancer drug activities last week when Bristol Myers Squibb agreed to pay up to $11.1 billion to jointly develop a next-generation cancer immunotherapy that could take on rival Merck & Co's best-selling drug Keytruda.
Each CureVac share will be exchanged for about $5.46 in BioNTech American depositary shares, or ADS, but subject to a so-called collar mechanism, BioNTech said.
If the 10-day volume-weighted average price of BioNTech ADS shortly before the closing of the offer exceeds $126.55, the exchange ratio would be 0.04318, and if the price is lower than $84.37, the exchange ratio would be 0.06476.
BioNTech said the deal was supported by SAP SE co-founder and football investor Dietmar Hopp, who holds a stake of about 37% in CureVac.
The German government, owner of about 13% in CureVac for its financial backing during the pandemic, said it welcomed in principle the creation of a "new German biotech champion", and that it would review the offer.
France and Saudi Arabia have agreed on plans for a $7 billion manga-themed amusement complex near Paris, inspired by the hugely popular Japane...
Britain and France have pledged stronger military support for Ukraine, including access to classified technology for Storm Shadow missile productio...
Saudi Arabia and France have reaffirmed their support for Palestinian statehood and called for Israel to withdraw from all Lebanese territory, as t...
Iran on Saturday denounced U.S. plans to announce new sanctions that could put further strain on the Islamic Republic's economy and have an impact on its most important trading partners including China.
Ukraine’s President Volodymyr Zelenskyy said on Monday that Kyiv wants peace but will not surrender to Russia, as foreign leaders joined Independence Day events marking 35 years since Ukraine’s independence.
A newly created pro-government political party has secured a commanding victory in Kazakhstan's snap parliamentary election, according to exit polls, strengthening President Kassym-Jomart Tokayev's influence at a pivotal moment in the country's political transition.
Only four commodity vessels crossed the Strait of Hormuz on Sunday, following 13 transits a day earlier, as disruptions continue to restrict traffic through the key energy chokepoint.
Ukrainian President Volodymyr Zelenskyy has rejected calls for a wartime election, arguing that holding a vote while Russia's full-scale invasion continues would divide the country and undermine national unity.
Australia has confirmed its first case of H5N1 bird flu in a mammal after the virus was detected in a dead long-nosed fur seal in South Australia, authorities said.
Malaysia is facing a sharp rise in dengue infections, with the capital Kuala Lumpur and the wider Klang Valley emerging as the main centres of concern.
The Democratic Republic of the Congo’s Ebola outbreak has surpassed 5,000 confirmed cases, with the death toll reaching 2,378, according to the latest government data.
The Democratic Republic of Congo says the number of confirmed Ebola cases has risen to more than 5,000, with more than 2,300 deaths. Delayed detection, weak surveillance, funding shortages and conflict have allowed the virus to spread faster than in any previous epidemic at the same stage.
Australia warned on Monday (3 August) of a wider spread of H5N1 bird flu after its first confirmed mass mortality event among seabirds killed about 50 greater crested terns off the coast of South Australia, south of Adelaide.
You can download the AnewZ application from Play Store and the App Store.
What is your opinion on this topic?
Leave the first comment